| pubmed-article:1847967 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C1519429 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0439801 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:1847967 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:1847967 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1847967 | pubmed:dateCreated | 1991-4-9 | lld:pubmed |
| pubmed-article:1847967 | pubmed:abstractText | Between March 1986 and May 1988, the Southwest Oncology Group enrolled 58 previously untreated patients with limited small-cell lung cancer on a treatment program that administered high-dose cyclophosphamide (150 mg/kg) as late intensification. Treatment consisted of induction chemo-radiotherapy, (weeks 1 to 11), consolidation chemotherapy (weeks 11 to 18), and intensification (week 18). Median age was 61.5 years. Eighty-nine percent of patients had a Southwest Oncology Group (SWOG) performance status of 0-1. Twenty-one patients completed all prescribed treatments. There were seven treatment-related deaths, four as a result of intensification. Fifty-six patients are available for response analysis. Thirty-two patients achieved a complete remission (CR) (57%) and fifteen achieved a partial remission (PR) (26%). Median survival for all patients is 11.1 months. Among the 21 patients who received intensification, nine remain alive in a CR with a median survival of 27 months. This sequence of treatments was not associated with a survival advantage for the group as a whole, possibly because of the toxicity of induction and consolidation treatment and the delayed administration of high-dose cyclophosphamide. | lld:pubmed |
| pubmed-article:1847967 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847967 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847967 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847967 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1847967 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847967 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1847967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1847967 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1847967 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:1847967 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:1847967 | pubmed:author | pubmed-author:LivingstonR... | lld:pubmed |
| pubmed-article:1847967 | pubmed:author | pubmed-author:RivkinS ESE | lld:pubmed |
| pubmed-article:1847967 | pubmed:author | pubmed-author:McCullochJ... | lld:pubmed |
| pubmed-article:1847967 | pubmed:author | pubmed-author:CrowleyJJ | lld:pubmed |
| pubmed-article:1847967 | pubmed:author | pubmed-author:GoodmanG EGE | lld:pubmed |
| pubmed-article:1847967 | pubmed:author | pubmed-author:AlbainKK | lld:pubmed |
| pubmed-article:1847967 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1847967 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:1847967 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1847967 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1847967 | pubmed:pagination | 453-7 | lld:pubmed |
| pubmed-article:1847967 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:meshHeading | pubmed-meshheading:1847967-... | lld:pubmed |
| pubmed-article:1847967 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1847967 | pubmed:articleTitle | Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. | lld:pubmed |
| pubmed-article:1847967 | pubmed:affiliation | Puget Sound Oncology Consortium, Seattle, WA. | lld:pubmed |
| pubmed-article:1847967 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1847967 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1847967 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1847967 | pubmed:publicationType | Multicenter Study | lld:pubmed |
